// App-Quantinova.ai

TPS7573 : A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.

Researchers

Presenter

  • Philippe Armand

Principal Investigators

  • Margaret Ann Shipp

  • John Kuruvilla

  • Graham P Collins

  • Rod Ramchandren

  • John Timmerman

  • Anne Sumbul

  • Mary M. Ruisi

  • Kazunobu Kato

  • Stephen Maxted Ansell

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom

  • Barbara Ann Karmanos Cancer Institute, Detroit, MI

  • UCLA Care Center, Los Angeles, CA

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • dacarbazine Intravenous

  • Vinblastine

  • Doxorubicin

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02181738

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved